topotecan has been researched along with pf 00299804 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, Z; Fu, L; Guo, X; Luo, M; To, KKW; Wang, F; Wang, X; Yan, S; Zhang, J | 1 |
1 other study(ies) available for topotecan and pf 00299804
Article | Year |
---|---|
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Membrane; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Mice; Models, Biological; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Topotecan; Xenograft Model Antitumor Assays | 2018 |